NRX Pharmaceuticals (NRXP) Profit After Tax (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Profit After Tax data on file, last reported at -$1.4 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 74.6% year-over-year to -$1.4 million in Q1 2026; TTM through Mar 2026 was -$24.5 million, a 1.51% decrease from a year earlier, with the FY2025 full-year figure at -$28.6 million, down 13.83% from the prior year.
• Profit After Tax for Q1 2026 stood at -$1.4 million, down from $400000.0 in the prior quarter.
• Over the last five years, Profit After Tax for NRXP reached as high as $400000.0 in Q4 2025 and fell as low as -$17.6 million in Q2 2025.
• Historically, Profit After Tax has averaged -$7.0 million across 5 years, with a median of -$6.5 million in 2024.
• Across the five-year window, Profit After Tax sank 5867.52% in 2022 and jumped 104.41% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$10.2 million in 2022, then surged by 57.88% to -$4.3 million in 2023, then plunged by 110.41% to -$9.1 million in 2024, then soared by 104.41% to $400000.0 in 2025, then slumped by 450.0% to -$1.4 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$1.4 million in Q1 2026, $400000.0 in Q4 2025, and -$5.9 million in Q3 2025.